Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,606,609
  • Shares Outstanding, K 237,664
  • Annual Sales, $ 44,580 K
  • Annual Income, $ -328,070 K
  • 60-Month Beta 0.82
  • Price/Sales 41.94
  • Price/Cash Flow N/A
  • Price/Book 3.16
Trade RXRX with:

Options Overview Details

View History
  • Implied Volatility 78.48% ( +0.07%)
  • Historical Volatility 82.96%
  • IV Percentile 25%
  • IV Rank 37.57%
  • IV High 135.52% on 02/27/24
  • IV Low 44.15% on 10/03/23
  • Put/Call Vol Ratio 0.26
  • Today's Volume 3,453
  • Volume Avg (30-Day) 4,242
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 130,884
  • Open Int (30-Day) 127,733

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.31
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.38
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +27.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.89 +25.36%
on 09/04/24
8.16 -9.64%
on 08/26/24
+0.64 (+9.46%)
since 08/16/24
3-Month
5.89 +25.36%
on 09/04/24
9.86 -25.21%
on 06/25/24
-2.32 (-23.94%)
since 06/18/24
52-Week
4.97 +48.44%
on 11/01/23
15.74 -53.13%
on 02/27/24
-1.35 (-15.49%)
since 09/18/23

Most Recent Stories

More News
Is Recursion Pharmaceuticals a Warren Buffett Stock?

Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider.

ORCL : 164.82 (-1.58%)
RXRX : 7.10 (+5.03%)
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Merging with a former rival will bolster its capabilities.

NVDA : 114.64 (-0.82%)
RXRX : 7.10 (+5.03%)
EXAI : 5.34 (+6.16%)
Is Recursion Pharmaceuticals Stock a Buy?

We'll know a little more about the biotech's prospects in a year and a half.

NFLX : 692.42 (-2.05%)
AAPL : 220.33 (+1.63%)
RXRX : 7.10 (+5.03%)
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END

AVAI : 0.6114 (+52.85%)
RXRX : 7.10 (+5.03%)
EXAI : 5.34 (+6.16%)
TWST : 48.61 (+1.97%)
IQV : 245.70 (+2.38%)
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

AVAI : 0.6114 (+52.85%)
RXRX : 7.10 (+5.03%)
EXAI : 5.34 (+6.16%)
TWST : 48.61 (+1.97%)
IQV : 245.70 (+2.38%)
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Efficiency in core processes is set to increase substantially due to AI.

RXRX : 7.10 (+5.03%)
DNA : 7.44 (+9.25%)
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move

There isn't much to suggest these businesses are actually vulnerable.

RXRX : 7.10 (+5.03%)
LLY : 909.36 (+0.35%)
VKTX : 65.14 (+3.50%)
PFE : 29.84 (+0.03%)
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.

EXAI : 5.34 (+6.16%)
RXRX : 7.10 (+5.03%)
Recursion Pharmaceuticals: Q2 Earnings Snapshot

Recursion Pharmaceuticals: Q2 Earnings Snapshot

RXRX : 7.10 (+5.03%)
Is Recursion Pharmaceuticals a Millionaire-Maker?

It's likely to experience a lot of growth.

RXRX : 7.10 (+5.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 7.26
2nd Resistance Point 7.15
1st Resistance Point 6.95
Last Price 7.10
1st Support Level 6.65
2nd Support Level 6.54
3rd Support Level 6.34

See More

52-Week High 15.74
Fibonacci 61.8% 11.63
Fibonacci 50% 10.35
Fibonacci 38.2% 9.08
Last Price 7.10
52-Week Low 4.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar